Glipy OD 100mg Tablet SR contains Vildagliptin 100mg, a potent oral antihyperglycemic agent used in the management of type 2 diabetes mellitus. Vildagliptin belongs to the class of dipeptidyl peptidase-4 (DPP-4) inhibitors, which work by enhancing the levels of incretin hormones, thereby increasing insulin secretion and decreasing glucagon release in a glucose-dependent manner. This dual action helps improve glycemic control without causing significant hypoglycemia. Glipy OD 100mg Tablet SR is formulated as a sustained-release preparation to provide a prolonged therapeutic effect, allowing once-daily dosing and improving patient compliance. It is indicated as monotherapy or in combination with other antidiabetic agents such as metformin or insulin when diet and exercise alone do not achieve adequate glycemic control. The medication is generally well tolerated, with a low risk of adverse effects; however, patients should be monitored for potential side effects including headache, dizziness, and gastrointestinal disturbances. Renal function should be assessed prior to initiation and periodically during treatment, as dose adjustments may be necessary in renal impairment. Glipy OD 100mg Tablet SR should be used under medical supervision, with regular monitoring of blood glucose levels to optimize therapeutic outcomes and minimize the risk of complications associated with diabetes mellitus.